IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Cysteinyl leukotrienes levels and their receptors expression in colonic mucosa of patients with inflammatory bowel disease
Autor/es:
GABRIELA MORA; P. CATUOGNO; JULIETA ALCAIN; MÓNICA VERMEULEN; A. ANDRUSH
Lugar:
Cancún
Reunión:
Congreso; Latin American Congress on Autoimmunity; 2017
Institución organizadora:
Autoimmunity Network
Resumen:
Cysteinyl leukotrienes are lipid mediators derived from the metabolism of arachidonic acid. They are potent proinflammatory mediators associated with asthma, arthritis, psoriasis, ulcerative colitis, etc. Their effects occur through 2 types of membrane receptors: CysLTR I and II. Objective: To evaluate the levels of LTC4 and its receptor?s expression in colonic mucosa of patients with inflammatory bowel disease (IBD). Patients and methods: Colon biopsies of patients with diagnosis of IBD (OMS) were obtained through videocolonoscopy. Samples were analyzed with hematoxylin-eosin and semiquantitatively classified for neutrophilic recruitment. CysLTR type 1 y 2 were determined (RT-PCR), and LTC4 and IL-8 (ELISA). Control group were sex and age matched patients undergoing conventional screening for colorectal cancer (OMS). The project was approved by the institutional ethics committee. Results: Twelve patients (6 women, 6 men) medium aged 49.75 years-old were compared with 12 controls (7 women, 5 men), 50.5 years-old. Significant increase in neutrophil percentages and IL-8 levels at the transversal colon and sigmoid rectum were found (Figure1 Ai/Aii - Bi/Bii) in patients versus controls. This correlated positively with CysLTR1 and LTC4 levels (p=0.01, Fisher´s test). These findings seemed more prominent in patients with extraintestinal manifestations (one patient with ulcerative colitis plus psoriasis, autoimmune hepatitis and type I diabetes, and two other patients, one with ulcerative colitis and other with Crohn?s, both with arthritis). Conclusion: Our results may indicate that LTC4 plays a central role in the gut?s mucosa inflammatory response of our group of patients with IBD, and particularly in those with extraintestinal manifestations.